Entera Bio
ENTX
6 hedge funds and large institutions have $3.1M invested in Entera Bio in 2018 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 1 closing their positions.
64,010% more capital inflows, than outflows
Capital inflows: $1.28M | Capital outflows: $2K
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
50% more funds holding
Funds holding: 4 → 6 (+2)
2.25% more ownership
Funds ownership: 6.72% → 8.98% (+2.3%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wildcat Capital Management
New York
|
+$1.01M |
| 2 |
DLD Asset Management
New York
|
+$124K |
| 3 |
FNY Investment Advisers
New York
|
+$75.6K |
| 4 |
Worth Venture Partners
Fort Lee,
New Jersey
|
+$71.3K |
| 5 |
Tower Research Capital (TRC)
New York
|
+$10 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$2K |
ENTX Hedge Fund Activity: Q4 2018 in Review
6 of the 4,506 institutional investors tracked by Wall St. Rank reported a position in Entera Bio (ENTX) for Q4 2018, worth a combined $3.1M — down 25% from $4.11M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new ENTX positions and 1 closed out — a net gain of 2 holders — while 2 added to existing stakes and 0 trimmed.
The largest buyer was Wildcat Capital Management, opening a new position worth an estimated $1.01M. The largest seller was UBS Group, exiting entirely with an estimated $2K sold.
- 6 institutional investors held Entera Bio (ENTX) as of Q4 2018, up from 4 in Q3 2018.
- Funds reported $3.1M of Entera Bio stock for Q4 2018, down 25% quarter-over-quarter.
- 3 funds opened new Entera Bio positions in Q4 2018 and 1 closed out, a net change of +2 holders.
- The largest Entera Bio buyer in Q4 2018 was Wildcat Capital Management, an estimated $1.01M added.
- The largest Entera Bio seller in Q4 2018 was UBS Group, an estimated $2K sold.
Based on aggregated 13F filings for Q4 2018.